MRNS

Marinus Pharmaceuticals, Inc. (MRNS) | Rumor.io

Marinus Pharmaceuticals

MRNS

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about MRNS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Dec 30

Marinus Pharmaceuticals, Inc. (MRNS) has been acquired by Immedica for $0.55 per share, resulting in a 46% price increase.
Ztalmy, an FDA-approved treatment for absence seizures, is a key asset of MRNS and is considered undervalued, with some analysts estimating its value to be $1.48 or more per share.
One investor believes MRNS is significantly undervalued, with a potential 78% upside, and is seeking to understand why others are selling shares.

Generated by AI

Sentiment

Of the messages about MRNS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +22.71
Bearish	—	—	—	0% -22.71

Bullish· Oct 25

Marinus Pharmaceuticals has an approved drug worth over $100 million, with revenue expected to grow substantially through 2030.
The company's FDA-approved drug and valuable assets make it a prime target for a strategic acquisition or merger, potentially leading to significant returns.
With its heavily oversold RSI and exceptional intrinsic value potential, Marinus Pharmaceuticals is considered a highly undervalued stock with significant short-term and medium-term gains potential.

Bearish· Oct 24

$MRNS is facing significant cash flow issues, with $35 million burned per quarter and only $25 million in cash reserves, potentially leading to bankruptcy.
The company's debt of $57 million and tangible assets of $47 million or less make it vulnerable to bankruptcy, with some analysts questioning the difference between bankruptcy and current circumstances.
Marinus Pharmaceuticals' stock has experienced a significant decline, with some investors suggesting it could reach $0.20 and others wondering if the company will survive the current quarter without additional debt or offerings.

Generated by AI

Topics

Of the messages about MRNS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0%
Announcements	100%	100%	100%	100%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	0%

Earnings· May 2

Marinus Pharmaceuticals reported earnings, beating expectations.
The company's update raised some doubts, but the top-line data for its oral product in Q4 was positive.
The earnings report did not reveal any new information.

Analysts· Mar 22

Analyst consensus on Marinus Pharmaceuticals ($MRNS) is a Strong Buy with an average price target of $25.40, implying a 182.2% upside from current levels.
Analysts have raised price targets for $MRNS, with JMP Securities raising its target to $22, Truist Financial raising its target to $50, and HC Wainwright maintaining a BUY with a target of $38.
Analysts have maintained a positive outlook for $MRNS, with SVB Leerink, JMP Securities, and Truist Securities all maintaining Buy or Outperform ratings and raising or maintaining price targets.

Announcements· Nov 17

Marinus Pharmaceuticals has entered into a collaboration and supply agreement with Tenacia Biotechnology for the development and commercialization of ganaxolone in China.
Marinus Pharmaceuticals has announced the appointment of CEO Scott Braunstein, M.D., as Chairman of the Board, and the departure of three directors.
Marinus Pharmaceuticals has added $10 million to its balance sheet and has announced a collaboration with Tenacia Biotechnology for the development and commercialization of ganaxolone in China.

Technical Analysis· Apr 16

Marinus Pharmaceuticals, Inc. ($MRNS) is oversold, with a potential bottom at 1.20, and increasing buying interest.
The stock is showing signs of a breakout, with decreasing limit sell orders and a potential move above the 1.40 range.
Technical indicators, including the RSI and A/D line, suggest a bottoming process, with volume and price action supporting a potential move higher.

Generated by AI

Community

Of the messages about MRNS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	46.76%
Newcomers	0%	0%	0%	53.24%

Regulars· Apr 15

The interim results of the RAISE trial for Marinus Pharmaceuticals' (MRNS) RSE indication did not meet the pre-defined stopping criteria, leading to a significant market drop, but the company believes the trial's outcome will be determined once the full data set is analyzed.
The company's best shot at breaking even is in the orphan pediatric indications and extended IP via formulation work, which could be a key area of focus for Marinus Pharmaceuticals moving forward.
The company's valuation has fallen to its base business, CDKL5, which has a market size of $150m, and assuming a peak of $50m, the stock could be attractive once again, with a potential multiple of 2x due to the lack of COM, method of use/formulation patents.

Newcomers· Apr 16

Many newcomers are discussing $MRNS as a potential reversal play, with some pointing to its oversold state and low market capitalization.
There are concerns about the company's product sales and upcoming data disclosure in 2024, which could impact its stock price and market capitalization.
Analyst Brian Skorney has downgraded $MRNS from $20 to $2, citing a decrease in potential upside, which has led to a significant decrease in the stock's price target.

Generated by AI

Also Discussed

Investors talking about MRNS also mention

#	Name	Attention
1	SAGE - Sage Therapeutics, Inc.	——
2	EVOK - Evoke Pharma, Inc.	——
3	Cellectar Biosciences, Inc.CLRB	0%new
4	Vericel CorporationVCEL	0%0
5	Verastem Inc.VSTM	0%0
6	ALIM - Alimera Sciences, Inc.	——
7	BLPH - Bellerophon Therapeutics, Inc.	——
8	Champions Oncology, Inc.CSBR	0%0
9	IMGN - ImmunoGen, Inc.	——
10	Pulmatrix Inc.PULM	0%0